6R-BH4
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Isolated Systolic Hypertension
Conditions
Isolated Systolic Hypertension, Endothelial Dysfunction
Trial Timeline
Dec 1, 2008 → May 1, 2009
NCT ID
NCT00802893About 6R-BH4
6R-BH4 is a phase 2 stage product being developed by BioMarin Pharmaceutical for Isolated Systolic Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT00802893. Target conditions include Isolated Systolic Hypertension, Endothelial Dysfunction.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00802893 | Phase 2 | Terminated |
| NCT00423280 | Phase 2 | UNKNOWN |
Competing Products
4 competing products in Isolated Systolic Hypertension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary | Daiichi Sankyo | Phase 3 | 77 |
| Sprifermin (AS902330) 10 mcg + Sprifermin (AS902330) 30 mcg + Sprifermin (AS902330) 100 mcg | Merck | Phase 2 | 52 |
| Rebif® | Merck | Phase 3 | 77 |
| romiplostim | Amgen | Phase 2 | 51 |